Scarica l'app Stockscreener
2.57
0.00%
0.00
Dopo l'orario di chiusura:
2.57
Precedente Chiudi:
$2.57
Aprire:
$2.57
Volume 24 ore:
1.43M
Relative Volume:
1.74
Capitalizzazione di mercato:
$110.79M
Reddito:
$51.13M
Utile/perdita netta:
$-93.80M
Rapporto P/E:
-1.1525
EPS:
-2.23
Flusso di cassa netto:
$-129.10M
1 W Prestazione:
-0.39%
1M Prestazione:
+16.03%
6M Prestazione:
+78.47%
1 anno Prestazione:
+86.23%
Intervallo 1D:
$2.55
$2.58
Intervallo di 1 settimana:
$2.55
$2.655
Portata 52W:
$0.89
$2.66
Repare Therapeutics Inc Stock (RPTX) Company Profile
Nome
Repare Therapeutics Inc
Settore
Industria
Telefono
(857) 412-7018
Indirizzo
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Confronta RPTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
2.57 | 110.79M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-06-09 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Iniziato | CapitalOne | Overweight |
| 2022-04-12 | Downgrade | Stifel | Buy → Hold |
| 2022-03-17 | Ripresa | Goldman | Buy |
| 2021-09-23 | Iniziato | Stifel | Buy |
| 2021-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-28 | Iniziato | Guggenheim | Buy |
| 2021-03-01 | Iniziato | Berenberg | Buy |
| 2020-10-28 | Iniziato | Northland Capital | Outperform |
| 2020-07-14 | Iniziato | Cowen | Outperform |
| 2020-07-14 | Iniziato | Goldman | Neutral |
| 2020-07-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Repare Therapeutics Inc Borsa (RPTX) Ultime notizie
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug - MSN
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Nigeria
Repare’s Sale Sparks Concerns: Time to Sell? - StocksToTrade
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX) - MarketBeat
Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million - El-Balad.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Repare Therapeutics Faces Scrutiny Amid Sale Deal - timothysykes.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead - GuruFocus
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln - Nasdaq
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Bluefield Daily Telegraph
Order Flow Trends Show Accumulation in Graphite India LimitedPortfolio Risk Assessment & Free Powerful Profit Generation - earlytimes.in
Will Repare Therapeutics Inc. stock gain from lower inflationEarnings Surprise Analysis & Our Picks = Your Future Gains - bollywoodhelpline.com
Can Repare Therapeutics Inc. stock double in next 5 yearsJuly 2025 Weekly Recap & Daily Oversold Bounce Ideas - Улправда
Repare Therapeutics Announces Resignation of Chief Scientific Officer - TradingView — Track All Markets
Repare Therapeutics Inc. Announces Resignation Ofmichael Zinda as Chief Scientific Officer, Effective December 31, 2025 - marketscreener.com
Why Repare Therapeutics Inc. stock is considered a top pickWeekly Market Report & Stepwise Swing Trade Plans - DonanımHaber
XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR - MSN
Why Repare Therapeutics Inc. stock is in analyst buy zone2025 Geopolitical Influence & Safe Swing Trade Setups - Улправда
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights - Sahm
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-RPTX, FRGE, CSGS, FIZN - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Benzinga
Repare Therapeutics Inc. (NASDAQ:RPTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Repare Therapeutics announces shareholder meeting for acquisition approval - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN - Sahm
Repare Therapeutics Announces Shareholder Meeting for Acquisition Approval - TipRanks
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Repare Therapeutics (RPTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Levels Update: Will Repare Therapeutics Inc. stock gain from lower inflation2025 AllTime Highs & Expert Verified Movement Alerts - moha.gov.vn
Will Repare Therapeutics Inc. stock deliver strong dividend growth2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerRPTX, AXTA, WTG and SEMR - Eastern Progress
Risk Report: Why Repare Therapeutics Inc. stock is in analyst buy zone2025 Price Momentum & Daily Price Action Insights - moha.gov.vn
Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Repare Therapeutics Inc Azioni (RPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):